vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Ares Commercial Real Estate Corp is the larger business by last-quarter revenue ($13.2M vs $9.3M, roughly 1.4× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -29.2%, a 29.9% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -24.5%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
ACRE vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $9.3M |
| Net Profit | $-3.9M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | -29.2% | 5.3% |
| Net Margin | -29.2% | 0.6% |
| Revenue YoY | -24.5% | -3.0% |
| Net Profit YoY | 63.8% | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $9.3M | ||
| Q3 25 | $14.1M | $6.9M | ||
| Q2 25 | $12.6M | $7.7M | ||
| Q1 25 | $14.9M | $6.8M | ||
| Q4 24 | $17.5M | $9.6M | ||
| Q3 24 | $16.7M | $8.8M | ||
| Q2 24 | $16.8M | $8.4M | ||
| Q1 24 | $18.7M | $6.8M |
| Q4 25 | $-3.9M | $58.0K | ||
| Q3 25 | $4.7M | $-1.6M | ||
| Q2 25 | $-11.0M | $-2.6M | ||
| Q1 25 | $9.3M | $-2.1M | ||
| Q4 24 | $-10.7M | $-4.6M | ||
| Q3 24 | $-5.9M | $-2.1M | ||
| Q2 24 | $-6.1M | $-91.0K | ||
| Q1 24 | $-12.3M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | -29.2% | 5.3% | ||
| Q3 25 | 33.0% | -16.9% | ||
| Q2 25 | -87.8% | -30.1% | ||
| Q1 25 | 64.4% | -25.0% | ||
| Q4 24 | -61.0% | -44.7% | ||
| Q3 24 | -35.3% | -18.2% | ||
| Q2 24 | -36.5% | -5.7% | ||
| Q1 24 | -65.9% | -42.7% |
| Q4 25 | -29.2% | 0.6% | ||
| Q3 25 | 33.0% | -23.4% | ||
| Q2 25 | -87.8% | -33.6% | ||
| Q1 25 | 62.5% | -31.2% | ||
| Q4 24 | -60.9% | -47.6% | ||
| Q3 24 | -35.3% | -23.6% | ||
| Q2 24 | -36.5% | -1.1% | ||
| Q1 24 | -65.9% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | — | $-0.51 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $7.9M |
| Total DebtLower is stronger | $948.2M | $15.3M |
| Stockholders' EquityBook value | $509.6M | $2.9M |
| Total Assets | $1.6B | $30.5M |
| Debt / EquityLower = less leverage | 1.86× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $7.9M | ||
| Q3 25 | $84.9M | $7.1M | ||
| Q2 25 | $90.0M | $6.0M | ||
| Q1 25 | $125.5M | $6.5M | ||
| Q4 24 | $63.8M | $7.3M | ||
| Q3 24 | $68.9M | $7.1M | ||
| Q2 24 | $70.6M | $5.5M | ||
| Q1 24 | $99.5M | $5.2M |
| Q4 25 | $948.2M | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | $718.5M | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $509.6M | $2.9M | ||
| Q3 25 | $521.0M | $1.3M | ||
| Q2 25 | $523.7M | $532.0K | ||
| Q1 25 | $542.1M | $3.0M | ||
| Q4 24 | $540.1M | $5.0M | ||
| Q3 24 | $563.8M | $9.4M | ||
| Q2 24 | $582.3M | $9.5M | ||
| Q1 24 | $601.1M | $9.4M |
| Q4 25 | $1.6B | $30.5M | ||
| Q3 25 | $1.4B | $30.7M | ||
| Q2 25 | $1.4B | $29.5M | ||
| Q1 25 | $1.5B | $33.0M | ||
| Q4 24 | $1.8B | $34.9M | ||
| Q3 24 | $1.9B | $39.4M | ||
| Q2 24 | $2.1B | $38.8M | ||
| Q1 24 | $2.1B | $39.2M |
| Q4 25 | 1.86× | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | 1.33× | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $-239.0K | ||
| Q3 25 | $3.8M | $-64.0K | ||
| Q2 25 | $4.9M | $-1.9M | ||
| Q1 25 | $8.0M | $-550.0K | ||
| Q4 24 | $35.5M | $703.0K | ||
| Q3 24 | $8.4M | $-302.0K | ||
| Q2 24 | $8.7M | $591.0K | ||
| Q1 24 | $11.4M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACRE
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
